

AstraZeneca



We put patients first



Since 2017, AstraZeneca have supported access to PSMA PET-CT scans for thousands of men with prostate cancer across regional & metro Australia¹

PSMA PET-CT is transforming patient care in patients with high-risk prostate cancer²

We follow the science



AstraZeneca partnered with AANMS to support the successful MSAC submission for PSMA PET-CT.

From **JULY 1st 2022**, there will now be equitable access for all eligible prostate cancer patients*



Contact your local AstraZeneca Oncology Business Manager for more information.



This brochure is 100% recyclable

*AstraZeneca supported the MSAC submission for PSMA PET-CT in prostate cancer by the Australasian Association of Nuclear Medicine Specialists. **PSMA PET-CT**: Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography. **References**: 1. Data on file. 2. Hofman M et al, for the proPSMA Study Group Collaborators. Lancet. 2020;395(10231):1208-16. ZOLADEX® is registered trademarks of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone 1800 805 342 or via <https://contactazmedical.astrazeneca.com> Or email Medical Information enquiries to medinfo.australia@astrazeneca.com. AU-13261. April 2022.